Navigation Links
AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
Date:8/17/2009

by at least 3 points. Notably, the 46% of patients who had received previous treatment for BPH showed an important mean improvement of 5 points, which is only slightly less than the 6 point improvement seen in treatment-naive patients. Maximum uroflow improved by 25%, from 10.3 to 12.5 ml/sec, and also the mean uroflow showed similar improvement.

Juergen Engel, Ph.D., AEterna Zentaris President and CEO stated, "Although the data received for the open-label safety study Z-041 with a nearly 6 point reduction in IPSS are in line with what we had observed in our Phase 2 program, we are disappointed by the failure to achieve the primary endpoint in the efficacy study Z-033. We remain committed to the ongoing Phase 3 program with cetrorelix in BPH and are working towards receiving the results of the second pivotal efficacy study Z-036 in November."

Herbert Lepor, M.D., Professor and Chairman, Department of Urology, at NYU School of Medicine, New York and Lead Investigator of the Z-033 trial added, "These findings are unexpected in light of the previous Phase 2 experience. Those data and the strength of the safety data available to date had given us confidence in this potential new treatment for BPH. It is now important to await results of the other placebo-controlled efficacy study Z-036."

Conference Call

The Company will host a conference call and webcast to discuss these results later today, Monday, August 17, 2009 at 10:00 a.m., Eastern Time.

Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Investors" section, or by telephone using the following numbers: (outside Canada): 800-588-4942. (Canada): 416-644-3426 or 514-807-8791. A replay of the webcast will also be available on the Company's website for a period of 30 days.

About the Phase 3 Program with Cetrorelix in BPH


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
2. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
3. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
4. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
5. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
6. AEterna Zentaris Receives US$10 Million from Institutional Investors
7. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
8. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
10. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
11. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... 14, 2014 iLab Solutions, the leader in ... new Director of Product Strategy. In this role, Michelle will ... sub-teams to guide in the development of iLab products. Her ... maximum possible benefit to the scientific community by offering the ...
(Date:1/14/2014)... January 14, 2014 Global Record ... innovative information technology solutions for patients, physicians, the ... stakeholders, announced today the signing of a three-year ... and Drug Administration (FDA). This initiative is ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Calif., July 22 CV Therapeutics,Inc. (Nasdaq: CVTX ... results for 2008 after the market closes on Thursday, ... at 5:00 p.m. EDT,2:00 p.m. PDT, on the company,s ... on to the Company,s website at, http://www.cvt.com and ...
... is bringing aboard Ashton S. Maaraba, a key Pharmacy, Pharmacy Services ... , ... (PRWEB) July 22, 2008 -- PharmaSmart International ... Ashton S. Maaraba, a key Pharmacy, Pharmacy Services & HBC industry ...
... U.S. Department of Energy,s Lawrence Berkeley National Laboratory (Berkeley ... performed the first scanning tunneling spectroscopy of graphene flakes ... latest in a series of surprising insights into the ... carbon: an unexpected gap-like feature in the energy spectrum ...
Cached Biology Technology:CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008 2Pharmasmart International Taps Top Executive Ashton Maaraba to Head Global Sales and Marketing 2A phonon floodgate in monolayer carbon 2A phonon floodgate in monolayer carbon 3A phonon floodgate in monolayer carbon 4A phonon floodgate in monolayer carbon 5
(Date:7/9/2014)... developed by researchers at the NIH,s National ... its collaborators to treat sickle cell disease ... business. The drug candidate, Aes-103, is the ... molecular mechanism of sickle cell disease. Baxter ... required for regulatory approval and commercialization. , ...
(Date:7/9/2014)... receptor antagonists can alleviate the symptoms of ... cognitive dysfunction and effectively scavenge amyloid beta ... (Aβ) vaccines reduced and eliminated Aβ deposition ... model, and significantly improved behavioral and cognitive ... First Affiliated Hospital of China Medical University, ...
(Date:7/9/2014)... inhabitants of the sea: tiny haptophytes of the type ... eye, when they are in bloom in spring, they ... on satellite images. "Together with other phytoplankton, Emiliania ... global photosynthesis output," states Prof. Dr. Georg Pohnert of ... the greenhouse gas carbon dioxide CO2 is ...
Breaking Biology News(10 mins):First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4Short circuit in the food web 2
... tropical parasitic disease that can lead to life-threatening heart ... than previously thought, according to research from The University ... for four years now, and this year the number ... professor of integrative biology and philosophy at The University ...
... Cincinnati, OH, October 6, 2011 -- Directly advertising food ... providers, and the American Academy of Pediatrics and the ... impact of advertising on children,s healthy food choices. ... Journal of Pediatrics explores the relationship between ...
... can ever know about long-gone creatures is what they ... resurrect actual specimens and compare their features with their ... Toronto biologists helping to create a seed bank that ... allowing them to measure evolution caused by global change. ...
Cached Biology News:Chagas disease may be a threat in South Texas, says researcher 2Study suggests children's food choices are affected by direct advertising and parental influence 2Seed time-capsule will aid study of plant evolution amid environmental change 2